Ductal carcinoma in situ (DCIS) of the breast: what is the safest treatment?

Cutuli, B.; Lemanski, C.; Nir, C. Cohen-Solal-Le; Lafontan, B. De; Gonzague-Casabianca, L.; Mignotte, H.; Servent, V.; Auvray, H.; Giard, S.; Charra-Brunaud, C.; Quétin, Philippe; Fay, Renaud

doi:10.1016/s0360-3016(03)01264-1

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the French Cancer Center Study, 6.2% of women were 70 years or older and the diagnosis was made by screening mammography in over half of these cases. After 75-months follow-up, LR rates in the TM and BCS groups were 3.8 and 22.2% respectively, however no LR occurred in the BCS + RT group [48].…”

Section: Specific Management Dilemmasmentioning

confidence: 87%

“…In one study, the presence of LCIS did not appear to affect the overall 10-year LR rate, but the proportion of invasive LR was been reported to be higher, 67% in lesions with LCIS compared to 43% for . In the French Cancer Centers series, the 7-year LR rate was similar in mixed lesions for patients treated with BCS alone, but greater in patients given adjuvant RT (23.8 and 11.7%, respectively) [48]. The hormone receptor profile of DCIS has prognostic and therapeutic implications.…”

Section: Histological Featuresmentioning

confidence: 96%

See 1 more Smart Citation

Current management of DCIS: a review

Patani

Cutuli

Mokbel

2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

Ductal carcinoma in-situ (DCIS) is a heterogeneous disease, in terms of its radiological characteristics, histological morphology and molecular attributes. This diversity is reflected in its natural history and influences optimal treatment strategy. A significant proportion of DCIS lesions behave in a clinically benign fashion and do not progress to invasive disease. Reliable identification of these patients could allow treatment to be less radical or safely omitted. Management should be tailored to the individual within the context of a multidisciplinary team. Approaches such as biological profiling and molecular analysis represent an opportunity to improve our understanding of the tumour biology of this condition and rationalise its treatment. This article reviews the management strategies for DCIS in the context of recent randomized trials, including the role of sentinel lymph node biopsy, adjuvant radiotherapy and tamoxifen.

show abstract

Section: Specific Management Dilemmasmentioning

confidence: 87%

Section: Histological Featuresmentioning

confidence: 96%